Quality Chemical Industry Limited (QCIL), a Ugandan manufacturer of anti-retroviral (ARV) drugs, has made a breakthrough in Rwanda 2012.
This follows earlier high level talks between the two governments which began in 2012. Last week, Rwanda’s trade and industry, Franccedilois Kanimba and his Ugandan counterpart, Amelia Kyambadde signed a bilateral Trade and Investment Framework agreement on pharmaceutical products.
It sets out the importance of promoting attractive investment climates in their respective countries while also expanding and diversifying trade in pharmaceuticals.
Kanimba said both parties have agreed on, “a set of items that include the promotion of trade and exchange of information in pharmaceutical products with a framework to promote medical research and development of pharmaceutical industry.”
Two years ago, President Paul Kagame was on a visit to Uganda during which he toured the QCIL plant at Luzira in Kampala.
With technical assistance from India-based CIPLA Limited, QCIL is now leading regional maker of ARVs in addition to also manufacturing anti-malarial drugs also under license from CIPLA.
Kagame’s favourable impressions of the complex led to a request by the Uganda government through President Museveni to look into possibilities of QCIL selling drugs to Rwanda.
“This comes to enhance the bonds of friendship and a spirit of cooperation in the pharmaceutical sector between Rwanda and Uganda, while ensuring access to medicines and other pharmaceutical modern technology to both countries citizens,” Kyambadde said during the signing of the deal.
Both parties agreed to establish a joint committee in pharmaceutical sector which will be responsible of monitoring bilateral trade and investment in pharmaceutical products and work to remove impediments to trade and investment between both countries. Long term plans include a similar factory being set up in Rwanda with assistance from QCIL.
Source : East African Business Week